SCHEMBL4354333

SCHEMBL4354333

CON(C)C(=O)c1cnc(SC)nc1N

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 8/20 0.40
ALDH1A1 P00352 7/20 0.40
RAB9A P51151 6/20 0.40
NPC1 O15118 6/20 0.40
NFKB1 P19838 2/20 0.40
NFKB2 Q00653 2/20 0.40
RELA Q04206 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
MAPT P10636 3/20 0.38
TSHR P16473 2/20 0.38
MAPK1 P28482 1/20 0.38
HSD17B10 Q99714 1/20 0.38
RECQL P46063 1/20 0.38
KDM4E B2RXH2 2/20 0.37
LMNA P02545 1/20 0.37
HPGD P15428 1/20 0.37
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2D6 P10635 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14625599 0.85 SMN1; SMN2 (0.41) SMN1; SMN2ALDH1A1RAB9ANPC1NFKB1
SCHEMBL4350600 0.85 SMN1; SMN2 (0.48) SMN1; SMN2ALDH1A1RAB9ANPC1NFKB1
SCHEMBL30566950 0.83 MEN1 (0.38) SMN1; SMN2ALDH1A1RAB9ANPC1MAPT
SCHEMBL24885909 0.81 ALDH1A1 (0.44) SMN1; SMN2ALDH1A1RAB9ANPC1NFKB1
SCHEMBL30078186 0.81 ALDH1A1 (0.44) SMN1; SMN2ALDH1A1RAB9ANPC1NFKB1
SCHEMBL7563419 0.79 SMN1; SMN2 (0.49) SMN1; SMN2ALDH1A1RAB9ANPC1NFKB1
SCHEMBL6073484 0.77 RAB9A (0.49) SMN1; SMN2ALDH1A1RAB9ANPC1NFKB1
SCHEMBL5209725 0.77 PIM1 (0.45) SMN1; SMN2ALDH1A1RAB9ANPC1NFKB1
SCHEMBL3084614 0.77 KDM4E (0.54) SMN1; SMN2ALDH1A1RAB9ANPC1NFKB1
SCHEMBL15874075 0.74 KMT2A (0.43) SMN1; SMN2ALDH1A1NPC1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040162303-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID JOSEPH (US) 2004-08-19 US claimed
US-7615634-B2 4-aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-10 US disclosed
US-7615634-B2 4-aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-10 US disclosed
US-7615634-B2 4-aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-10 US disclosed
US-7157455-B2 4-Aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2007-01-02 US disclosed
US-20060229330-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID J 2006-10-12 US disclosed
EP-1628619-A2 4-AMINOPYRIMIDINE-5-ONE F.HOFFMANN-LA ROCHE AG (CH) 2006-03-01 EP disclosed
US-20040162303-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID JOSEPH (US) 2004-08-19 US disclosed
WO-2004069139-A2 4-AMINOPYRIMIDIN-5-YL-METHANONE DERIVATIVES FOR INHIBITION OF CDK4 ACTIVITY F.HOFFMANN-LA ROCHE AG (CH) 2004-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162303-A1 4-aminopyrimidine-5-one derivatives CDK4, CDKL4, CDK6 SMN1; SMN2 2994/4885ALDH1A1 915/4885RAB9A 3765/4885
US-20060229330-A1 4-aminopyrimidine-5-one derivatives CDK4, CDKL4, CDK2 SMN1; SMN2 2768/4885ALDH1A1 1191/4885RAB9A 3418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.